Genomic Medicines – Sangamo Therapeutics Inc

Dr. Bettina Cockroft, M.D., SVP and CMO at Sangamo Therapeutics, Inc., a genomic medicine company, discusses their approach to treating disease and why genomic medicines are so important to the future of medicine.  She also talks about one of the latest therapies Sangamo has in a Phase 1/2 clinical trial for the treatment of Fabry disease, a rare, X-linked lysosomal storage disorder caused by a gene mutation in an enzyme responsible for breaking down fatty substances.

Bettina Cockroft, M.D., M.B.A., has served as Senior Vice President and Chief Medical Officer since September 2019 and oversees all clinical development activities and operations. She has over 20 years of experience in the biopharmaceutical industry and has worked across multiple therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at Cytokinetics, Inc., where she was responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career.Dr. Cockroft earned her M.B.A. at MIT Sloan School of Management and her M.D. from the University of Genova.